Genetic Test Evaluation

understanding how genetic tests impact patient management

ProMark Proteomic Prognostic Test (Metamark Genetics Inc.)

November 17, 2016

An estimated 180,890 new cases of prostate cancer will be diagnosed in 2016, which accounts for 10.7% of all new cancer cases in the United States. Prostate cancer is the second leading cause of cancer death in the United States, with approximately 12.9% of men being diagnosed during their lifetime. For men diagnosed with prostate cancer from 2006 to 2012, the 5-year survival rate is 98.9%. While survival rates are high, variability in the clinical stage of cancer at the time of diagnosis impacts survival rates, with 5-year survival rates of 29.3% if the cancer has metastasized. Patients with prostate cancer are at risk of side effects from overtreatment and undertreatment. Advancements in biomarker testing have recently given clinicians risk stratification options beyond clinicopathologic features of tumor biopsies to help determine the best treatment options for each patient. The current report focuses on one such biomarker test, the ProMark Proteomic Prognostic Test.